Archive for December, 2008



What’s new in Parkinson’s disease medications?

Azilect® reported to have potential to affect progression

On August 26, 2008 a news release issued by Teva Pharmaceutical Industries Ltd., manufacturers of the drug, Azilect®, reports that the results of the ADAGIO phase 3 trial indicate that early treatment with 1 mg of Azilect supports the potential for Azilect to have an effect on the progression of Parkinson’s.

The news release was issued at the 12th Congress of European Federation of Neurological Societies in Madrid, Spain. The data have yet to be published in a peer-reviewed journal.

Since 2006, Azilect® has been approved by Health Canada for treating Parkinson’s symptoms, however the only provincial drug plan that provides coverage is Quebec. The medication may be covered under private insurance plans

Stalevo now covered under Quebec drug plan

As of October 2008, Stalevo has been approved and is now available in Quebec. The Common Drug Review (CDR) has recommended that it also be listed in other provinces. The medication may be covered under private insurance plans. 

Stalevo Information Sheet English

Partnerships boost research funding

Partnering on research initiatives allows Parkinson Society Canada (PSC) to invest more money into more research that will ultimately benefit the over 100,000 Canadians living with Parkinson’s, their care partners, and families. It is the cornerstone of what we do as the largest non-government funder of Parkinson’s research in Canada.

 

PSC Research Announcements

http://www.parkinson.ca/site/c.kgLNIWODKpF/b.3536153/k.EFCA/PSC_Funded_Research.htm

What’s New in Your Community

British Columbia

Victoria

Alberta

Southern Alberta

Saskatchewan

Manitoba

Central and Northern Ontario

Southwestern Ontario

Ottawa

Quebec

Maritimes

Newfoundland and Labrador


Charitable registration number 10809 1786 RR0001
All material related to Parkinson's disease contained in Parkinson Post is solely for the information of the reader. It should not be used for treatment purposes. Specific articles reflect the opinion of the writer and are not necessarily the opinion of PSC.

Twitter Updates

Error: Twitter did not respond. Please wait a few minutes and refresh this page.